• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Diagnosis

Receiving a diagnosis of ALS/MND is a life-changing moment. This page explains what the diagnostic process typically involves and what people can expect in terms of how the disease progresses. It is intended as a general introduction. A neurologist or specialist will be the most important source of information for any individual situation.


How ALS/MND is diagnosed

There is no single test that confirms ALS/MND. Diagnosis is a process, and it can take time. A neurologist will typically conduct a series of assessments to identify signs of ALS/MND and to rule out other conditions that can cause similar symptoms.

The diagnostic process may include:

  • A detailed neurological examination to assess muscle strength, reflexes, coordination, and speech
  • Electromyography (EMG) and nerve conduction studies, which measure the electrical activity of muscles and nerves
  • MRI scans, to rule out other causes of symptoms such as spinal cord compression or stroke
  • Blood and urine tests, to exclude other conditions
  • In some cases, a muscle or nerve biopsy, or a lumbar puncture

Because ALS/MND shares some features with other neurological conditions, reaching a confirmed diagnosis can require multiple appointments and tests over a period of weeks or months. A second opinion from another specialist is a reasonable step, and many people find it helpful.

Once a diagnosis is confirmed, care is typically transferred to, or coordinated with, a multidisciplinary team. This team may include neurologists, physiotherapists, occupational therapists, speech therapists, respiratory specialists, dietitians, social workers, and others. For more on the care team and what it involves, see the Clinical Care section.


How ALS/MND progresses

ALS/MND affects each person differently. The rate and pattern of progression vary from one individual to the next, depending on factors such as which muscles are affected first, age at diagnosis, and overall health.

In most cases, ALS/MND begins with weakness or changes in one area — such as a hand, foot, or the muscles used for speaking or swallowing — and spreads over time to other parts of the body. The muscles that control breathing are typically affected as the disease progresses.

Cognitive and behavioural changes can also occur in some people living with ALS/MND, including difficulties with memory, language, or behaviour. These changes are more common in people who also have frontotemporal dementia (FTD), which overlaps with ALS/MND in a proportion of cases.

Because progression is variable, it is difficult to make precise predictions for any individual. A specialist or multidisciplinary care team is best placed to discuss what to expect based on a person’s specific situation.


Finding support after diagnosis

A diagnosis of ALS/MND affects not only the person diagnosed, but also family members and caregivers. Finding the right support early can make a significant difference.

The Alliance’s member associations provide support, information, and services to people living with ALS/MND and their families around the world. To find an association in your region, visit the Member Association directory.

Note: This page provides general information only. It is not a substitute for medical advice. Anyone with concerns about their symptoms or diagnosis should speak with a qualified healthcare professional.

Primary Sidebar

  • Conny van der Meijden, Netherlands

    Conny van der Meijden, Netherlands

  • Ian Gale, Australia

    Ian Gale, Australia

  • Greg Heydet, USA

    Greg Heydet, USA

  • Anita Forte, USA

    Anita Forte, USA

  • JP

    JP

  • Brian Parsons, Canada

    Brian Parsons, Canada

  • Joanne Pratt, Australia

    Joanne Pratt, Australia

  • Margarita Pizarro, Argentina

    Margarita Pizarro, Argentina

  • Jason Goodman, USA

    Jason Goodman, USA

  • Ali Var, Turkey

    Ali Var, Turkey

  • Josée Kolijn-de Man, Netherlands

    Josée Kolijn-de Man, Netherlands

  • Dick Dayton, USA

    Dick Dayton, USA

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Roy Taylor, Ireland

    Roy Taylor, Ireland
    roy

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • Roxana Canova, Argentina

    Roxana Canova, Argentina

  • Graham Johnson, Australia

    Graham Johnson, Australia

  • Olga Cosentino, Argentina

    Olga Cosentino, Argentina

  • Mark Miller, UK

    Mark Miller, UK

  • Lin Yong Yi, Taiwan

    Lin Yong Yi, Taiwan

  • Ching-Liang Chu, Taiwan

    Ching-Liang Chu, Taiwan

  • Verónica Isabel Castro Molina, Argentina

    Verónica Isabel Castro Molina, Argentina

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Mary Thomas, Australia

    Mary Thomas, Australia

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • David Watson, Scotland

    David Watson, Scotland

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Alex, Argentina

    Alex, Argentina

  • Xian-Zhang Niu, China

    Xian-Zhang Niu, China

  • Dr. Shelly Hoover, USA

    Dr. Shelly Hoover, USA

  • Zabun Nassar, England

    Zabun Nassar, England

  • Paul Launer, USA

    Paul Launer, USA

  • Lucy Lintott, Scotland

    Lucy Lintott, Scotland

  • Lee Millard, England

    Lee Millard, England

  • Maria Lucia Wood Saldanha, Brazil

    Maria Lucia Wood Saldanha, Brazil

  • Joy Blakeley, Australia

    Joy Blakeley, Australia

  • Zelina Brito, Brazil

    Zelina Brito, Brazil

  • Peng Yi-Wen, Taiwan

    Peng Yi-Wen, Taiwan

  • Marcel R. Wernard, Netherlands

    Marcel R. Wernard, Netherlands

  • Mikey Stone, ALS

    Mikey Stone, ALS

  • Claudette Sturk, Canada

    Claudette Sturk, Canada
    Picture2

  • Antonio Ventriglia, Belgium

    Antonio Ventriglia, Belgium

  • Barry de Reuver, Netherlands

    Barry de Reuver, Netherlands

  • Jack Buzby, USA

    Jack Buzby, USA

  • Brigitte Wernli, Switzerland

    Brigitte Wernli, Switzerland

  • Marcelo Farinelli, Brazil

    Marcelo Farinelli, Brazil

  • Patrick Shuma, Kenya

    Patrick Shuma, Kenya

  • David Solomon, UK

    David Solomon, UK

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Charlie Dourney, USA

    Charlie Dourney, USA

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login